Target Information

Target General Infomation
Target ID
T77431
Target Name
5-HT 3 receptor
Target Type
Clinical Trial
Disease Anxiety disorder [ICD9: 300, 311; ICD10: F32, F40-F42]
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3]
Chronic functional vomiting [ICD9: 536.2; ICD10: R11.10]
Generalized anxiety disorder; Major depressive disorder [ICD9:300, 300.02, 311, 296.2, 296.3, 710.0; ICD10: F32, F40-F42, F41.1, F33, M32]
Gastro-oesophageal reflux [ICD9: 530; ICD10: K21]
Gastric motility disorder [ICD10: K22.4]
Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10: A09, K58, K59.1]
Mood disorder [ICD10: F30-F39]
Nausea [ICD10: R11]
Substance dependence [ICD10: F10-F19]
Unspecified [ICD code not available]
BioChemical Class
Channels/Pores (TC=1)
Drugs and Mode of Action
Drug(s) LITOXETINE Drug Info Phase 3 Mood disorder [544832]
Renzapride Drug Info Phase 3 Irritable bowel syndrome [536224], [539568]
ZATOSETRON MALEATE Drug Info Phase 3 Anxiety disorder [551821]
DDP-225 Drug Info Phase 2 Irritable bowel syndrome [536224]
Lintopride Drug Info Phase 2 Nausea [534100]
Pumosetrag Drug Info Phase 2 Irritable bowel syndrome [536224]
BIMU-1 Drug Info Phase 1 Cognitive disorders [533870], [539484]
ITASETRON Drug Info Phase 1 Nausea [524948]
Pumosetrag Drug Info Phase 1 Gastro-oesophageal reflux [536224]
Tedatioxetine Drug Info Phase 1 Generalized anxiety disorder; Major depressive disorder [548243]
BRL-46470 Drug Info Discontinued in Phase 2 Anxiety disorder [539455], [544854]
DDP-225 Drug Info Discontinued in Phase 2 Chronic functional vomiting [536224]
E-3620 Drug Info Discontinued in Phase 2 Gastric motility disorder [545633]
Fabesetron Drug Info Discontinued in Phase 2 Irritable bowel syndrome [544894]
WAY-100289 Drug Info Discontinued in Phase 1 Anxiety disorder [544921]
CR-3124 Drug Info Terminated Substance dependence [548288]
Modulator (R)-zacopride Drug Info
BIMU-1 Drug Info [533870]
BRL-46470 Drug Info
CR-3124 Drug Info
DDP-225 Drug Info [1572591]
E-3620 Drug Info [1572591]
Fabesetron Drug Info
ITASETRON Drug Info [1572591]
Lintopride Drug Info [534100]
LITOXETINE Drug Info
Pumosetrag Drug Info
Renzapride Drug Info
S-21007 Drug Info
SC-52491 Drug Info
SC-54750 Drug Info
Tedatioxetine Drug Info [1572591]
WAY-100289 Drug Info [533730]
ZATOSETRON MALEATE Drug Info
References
Ref 524948ClinicalTrials.gov (NCT02259985) Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects. U.S. National Institutes of Health.
Ref 533870Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45.
Ref 534100The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
Ref 536224Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
Ref 539455(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2302).
Ref 539484(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 234).
Ref 539568(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 244).
Ref 544832Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001264)
Ref 544854Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001328)
Ref 544894Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001434)
Ref 544921Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001552)
Ref 545633Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004004)
Ref 548243Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023694)
Ref 548288Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024202)
Ref 551821Concise Dictionary of Pharmacological Agents: Properties and Synonyms, Dr. Ian Morton,I.K. Morton,Judith M. Hall. Page(298).
Ref
Ref 533730The selective 5-HT3 receptor antagonist, WAY100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system. Psychopharmacology (Berl). 1995 Feb;117(3):318-32.
Ref 533870Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45.
Ref 534100The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.